Related Experiment Video
Updated: May 16, 2026
09:53
Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
Published on: July 5, 2021
Gamma Knife surgery for central neurocytomas.
Bengt Karlsson1, Wan-Yuo Guo, Teo Kejia
1Division of Neurosurgery, National University Hospital, Singapore. nykuttram@yahoo.se
Journal of Neurosurgery
|December 5, 2012
Summary
Gamma Knife surgery (GKS) offers high tumor control rates for central neurocytoma (CN) remnants and recurrences. This study suggests GKS is a preferred treatment, though long-term data and hydrocephalus monitoring are crucial.
Area of Science:
- Neurosurgery
- Radiation Oncology
- Oncology
Background:
- Central neurocytoma (CN) management, especially for remnants and recurrences, lacks clear optimal strategies.
- Published large-scale patient series for Gamma Knife surgery (GKS) in CN are limited.
Purpose of the Study:
- To analyze the largest available patient population treated with GKS for central neurocytoma.
- To evaluate the efficacy and safety of GKS for CN remnants and recurrences.
Main Methods:
- Retrospective analysis of data from 42 patients treated with GKS for CN before July 1, 2010, across 5 centers.
- Median prescribed dose of 13 Gy (range 11-25 Gy) with follow-up ranging from 0.5 to 14.7 years (mean 6.1 years).
Main Results:
- Achieved 5- and 10-year tumor control rates of 91% and 81%, respectively.
- Reported no permanent complications; 45% of patients experienced ventricular system enlargement.
- Two cases of local progression and 2 of distant recurrence were observed.
Conclusions:
- GKS demonstrates a high tumor control rate and low complication rate, suggesting it as a preferred treatment for CN remnants/recurrences post-microsurgery.
- Further validation with longer follow-up and larger patient cohorts is necessary.
- Close patient monitoring for potential hydrocephalus is essential despite tumor control.
